ro 8-0576 has been researched along with lisuride in 4 studies
| Studies (ro 8-0576) | Trials (ro 8-0576) | Recent Studies (post-2010) (ro 8-0576) | Studies (lisuride) | Trials (lisuride) | Recent Studies (post-2010) (lisuride) |
|---|---|---|---|---|---|
| 214 | 63 | 67 | 756 | 80 | 31 |
| Protein | Taxonomy | ro 8-0576 (IC50) | lisuride (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.02 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.041 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.559 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.016 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0029 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0005 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0043 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0005 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.04 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.041 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.003 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.02 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0005 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.16 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0002 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0051 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A | 1 |
| Birkmayer, W | 1 |
| Caraceni, T; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A; Parati, E | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
1 trial(s) available for ro 8-0576 and lisuride
| Article | Year |
|---|---|
A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Topics: Administration, Oral; Benserazide; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Ergolines; Humans; Hydrazines; Infusion Pumps; Levodopa; Lisuride; Parkinson Disease; Severity of Illness Index | 1988 |
3 other study(ies) available for ro 8-0576 and lisuride
| Article | Year |
|---|---|
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine | 1981 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |